Advanced Therapy Medicinal Products have transformed treatment for severe diseases, but ensuring their safety pre-administration remains a challenge. Traditional Mycoplasma testing methods can cause delays, especially with high cell density and nucleic acid loads complicating QC workflows. Faster, validated methods are urgently needed to meet regulatory demands without sacrificing accuracy. With the demand for cell therapy growing, efficient QC testing is crucial for ensuring patient safety and treatment efficacy.
Read more from the-scientist.com
